Custom cancer vaccine tested in fight against deadly skin cancer
NCT ID NCT03929029
Summary
This early-stage study is testing the safety of a new, personalized vaccine designed to teach the immune system to attack a patient's specific melanoma. The vaccine is given alongside two approved immunotherapy drugs. The main goal is to find a safe dose for a new way of giving one of the drugs and to see if the combination causes severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.